Market Herald logo

Subscribe

Be the first with the news that moves the market
  • The Health Products Regulatory Authority approves Althea’s (AGH) CBD12:THC10 product to be used as prescription and supply in Ireland
  • The approval marks Althea’s entry into the Irish medicinal cannabis market, and the first stop of its planned European expansion
  • An application will follow for Althea CBD12:THC10 to be added to the Primary Care Reimbursement Service in the country to make the product free for prescribed Irish patients
  • The company is seeking further product approvals in the country
  • AGH shares are up 4.17 per cent, trading at 12.5 cents as of 2:14 pm AEST

Althea (AGH) has received approval from the Health Products Regulatory Authority (HPRA) for its CBD12:THC10 product to be used as prescription and supply in Ireland.

The approval marks Althea’s entry into the Irish medicinal cannabis market, and the first stop of its planned European expansion.

An application will follow for Althea CBD12:THC10 to be added to the Primary Care Reimbursement Service in Ireland as part of the Medicinal Cannabis Access Programme (MCAP).

The MCAP makes the product free of charge for Irish patients who are prescribed the treatment under the program.

This program makes it possible for a medical consultant to prescribe a cannabis-based treatment for a patient under their care where the patient has failed to respond to standard treatments, which includes treatment-resistant epilepsy and chemotherapy-induced nausea and vomiting.

CEO Joshua Fegen said the approval aligns with Althea’s European growth strategy.

“Having one of only a limited number of cannabis-based medicines approved for sale in Ireland is a massive advantage for Althea and when combined with our world-class medical education program, we aim to achieve positive and sustainable growth in Ireland over the years to come.”

Althea CBD12:THC10 is one of a limited number of medicinal cannabis products available for prescription and supply in Ireland.

The company is seeking further product approvals in the country.

AGH shares were up 4.17 per cent, trading at 12.5 cents as of 2:14 pm AEST.

AGH by the numbers
More From The Market Herald
Ballymore Resources (ASX:BMR) - Non Executive Chairman, Nick Jorss

" Ballymore Resources (ASX:BMR) intersects significant assays at Seventy Mile Mount

Ballymore Resources (ASX:BMR) has intersected significant assays in its initial drilling program at the Seventy Mile…

" Ballymore Resources (ASX:BMR) begins stage one drilling at Ruddygore

Ballymore Resources (ASX:BMR) has begun stage one drilling at the Ruddygore Prospect in North Queensland.

" Ballymore Resources (ASX:BMR) confirms displacement of Duffer lode at Dittmer mine, QLD

Ballymore Resources (ASX:BMR) has confirmed through diamond drilling that the historic Duffer lode at its Dittmer…

" Bannerman Energy (ASX:BMN) completes $40.7m institutional placement

Bannerman Energy (ASX:BMN) has raised $40.7 million via institutional placement, with the funds to be used…